These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

844 related articles for article (PubMed ID: 35190375)

  • 1. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
    Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
    N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
    Socinski MA; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kong S; Lee A; Coleman S; Zou W; McCleland M; Shankar G; Reck M
    J Thorac Oncol; 2021 Nov; 16(11):1909-1924. PubMed ID: 34311108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
    Nogami N; Barlesi F; Socinski MA; Reck M; Thomas CA; Cappuzzo F; Mok TSK; Finley G; Aerts JG; Orlandi F; Moro-Sibilot D; Jotte RM; Stroyakovskiy D; Villaruz LC; Rodríguez-Abreu D; Wan-Teck Lim D; Merritt D; Coleman S; Lee A; Shankar G; Yu W; Bara I; Nishio M
    J Thorac Oncol; 2022 Feb; 17(2):309-323. PubMed ID: 34626838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
    Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
    Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
    Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
    Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
    Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    Reck M; Wehler T; Orlandi F; Nogami N; Barone C; Moro-Sibilot D; Shtivelband M; González Larriba JL; Rothenstein J; Früh M; Yu W; Deng Y; Coleman S; Shankar G; Patel H; Kelsch C; Lee A; Piault E; Socinski MA
    J Clin Oncol; 2020 Aug; 38(22):2530-2542. PubMed ID: 32459597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
    Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
    BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Papillon-Cavanagh S; Doshi P; Dobrin R; Szustakowski J; Walsh AM
    ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32312757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.
    Liang Y; Maeda O; Kondo C; Nishida K; Ando Y
    PLoS One; 2024; 19(7):e0307580. PubMed ID: 39037971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
    Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
    J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.